Lexaria Welcomes Industry Veteran as New CEO
Lexaria Bioscience Corp. (NASDAQ:LEXX) announces a significant leadership change, with Richard Christopher appointed as the new CEO, effective August 31, 2024. Christopher, an industry veteran with over 30 years of experience in medical devices and pharmaceuticals, replaces Chris Bunka, who will remain as Chairman of the Board and Executive Strategic Advisor. The transition aligns with Lexaria's focus on advancing drug delivery in the GLP-1 marketplace and pharmaceutical industry collaborations.
The company's 100-day plan includes executing a Material Transfer Agreement with a pharmaceutical company, ongoing GLP-1 research studies, and preparing for a 2025 FDA-cleared Phase 1b hypertension study. Lexaria's DehydraTECH™ technology, developed since 2015, aims to enhance drug delivery kinetics, with a focus on cardio-metabolic, diabetes, weight loss, and hypertension sectors.
Lexaria Bioscience Corp. (NASDAQ:LEXX) annuncia un importante cambio di leadership, con Richard Christopher nominato nuovo CEO, efficace dal 31 agosto 2024. Christopher, un veterano del settore con oltre 30 anni di esperienza nei dispositivi medici e nei prodotti farmaceutici, sostituisce Chris Bunka, che rimarrà come Presidente del Consiglio e Consulente Strategico Esecutivo. Questa transizione è in linea con l'obiettivo di Lexaria di avanzare nella somministrazione di farmaci nel mercato GLP-1 e nelle collaborazioni nell'industria farmaceutica.
Il piano di 100 giorni dell'azienda prevede l'esecuzione di un Accordo di Trasferimento di Materiali con una società farmaceutica, studi di ricerca GLP-1 in corso, e la preparazione per uno studio di fase 1b sull'ipertensione approvato dalla FDA nel 2025. La tecnologia DehydraTECH™ di Lexaria, sviluppata dal 2015, mira a migliorare la cinetica della somministrazione dei farmaci, con un focus sui settori cardio-metabolici, diabete, perdita di peso e ipertensione.
Lexaria Bioscience Corp. (NASDAQ:LEXX) anuncia un cambio significativo en el liderazgo, con Richard Christopher nombrado nuevo CEO, efectivo a partir del 31 de agosto de 2024. Christopher, un veterano de la industria con más de 30 años de experiencia en dispositivos médicos y farmacéuticos, reemplaza a Chris Bunka, quien permanecerá como Presidente del Consejo y Asesor Estratégico Ejecutivo. Esta transición está en línea con el enfoque de Lexaria en avanzar en la entrega de medicamentos en el mercado de GLP-1 y en las colaboraciones dentro de la industria farmacéutica.
El plan de 100 días de la empresa incluye ejecutar un Acuerdo de Transferencia de Materiales con una empresa farmacéutica, estudios de investigación en GLP-1 en curso, y prepararse para un estudio de hipertensión de fase 1b aprobado por la FDA en 2025. La tecnología DehydraTECH™ de Lexaria, desarrollada desde 2015, busca mejorar la cinética de entrega de medicamentos, enfocándose en los sectores de cardio-metabólico, diabetes, pérdida de peso e hipertensión.
렉사리아 생명과학 주식회사 (NASDAQ:LEXX)는 리차드 크리스토퍼를 새로운 CEO로 임명한다고 발표했습니다. 이는 2024년 8월 31일부터 효력을 발생합니다. 30년 이상의 의료 기기 및 제약 분야 경험을 가진 산업 베테랑인 크리스토퍼는 이사회 의장 및 전략적 고문으로 남을 크리스 분카를 대신하게 됩니다. 이번 전환은 렉사리아의 GLP-1 시장에서 약물 전달을 촉진하는 데 초점을 맞추고 제약 산업과의 협업을 강화하기 위한 것입니다.
회사의 100일 계획에는 제약 회사와의 물질 이전 계약 체결, 진행중인 GLP-1 연구, 그리고 2025년 FDA 승인 1b 단계 고혈압 연구 준비가 포함되어 있습니다. 2015년부터 개발된 렉사리아의 DehydraTECH™ 기술은 심혈관 대사, 당뇨병, 체중 감소 및 고혈압 분야를 중점적으로 약물 전달 동역학을 향상시키는 것을 목표로 하고 있습니다.
Lexaria Bioscience Corp. (NASDAQ:LEXX) annonce un changement de leadership significatif, avec Richard Christopher nommé nouveau PDG, effectif à partir du 31 août 2024. Christopher, un vétéran de l'industrie avec plus de 30 ans d'expérience dans les dispositifs médicaux et les produits pharmaceutiques, remplace Chris Bunka, qui restera en tant que président du conseil d'administration et conseiller stratégique exécutif. La transition s'inscrit dans l'objectif de Lexaria d'avancer dans la délivrance de médicaments sur le marché du GLP-1 et de collaborer avec l'industrie pharmaceutique.
Le plan de 100 jours de l'entreprise comprend l'exécution d'un accord de transfert de matériel avec une entreprise pharmaceutique, des études de recherche GLP-1 en cours, et la préparation d'une étude de phase 1b sur l'hypertension approuvée par la FDA en 2025. La technologie DehydraTECH™ de Lexaria, développée depuis 2015, vise à améliorer la cinétique de délivrance des médicaments, en se concentrant sur les secteurs cardio-métaboliques, le diabète, la perte de poids et l'hypertension.
Lexaria Bioscience Corp. (NASDAQ:LEXX) kündigt einen bedeutenden Führungswechsel an, mit Richard Christopher, der zum neuen CEO ernannt wurde, ab dem 31. August 2024. Christopher, ein Branchenveteran mit über 30 Jahren Erfahrung in Medizintechnik und Pharmazie, ersetzt Chris Bunka, der als Vorsitzender des Vorstands und strategischer Vorstandberater bleibt. Der Wechsel steht im Einklang mit Lexarias Fokus auf die Verbesserung der Medikamentenabgabe im GLP-1-Markt und die Zusammenarbeit in der Pharmaindustrie.
Der 100-Tage-Plan des Unternehmens umfasst die Durchführung eines Material Transfer Agreements mit einem Pharmaunternehmen, laufende GLP-1-Forschungsstudien und die Vorbereitung auf eine 2025 von der FDA genehmigte Phase-1b-Studie zur Hypertonie. Die seit 2015 entwickelte DehydraTECH™-Technologie von Lexaria zielt darauf ab, die Kinetik der Medikamentenabgabe zu verbessern, mit einem Schwerpunkt auf den Bereichen kardiometabolisch, Diabetes, Gewichtsverlust und Hypertonie.
- Appointment of Richard Christopher as CEO, bringing extensive industry experience
- Chris Bunka remaining involved as Chairman and Executive Strategic Advisor
- Focus on advancing drug delivery in the GLP-1 marketplace
- Ongoing execution of Material Transfer Agreement with a pharmaceutical company
- Multiple GLP-1 research studies in progress
- Planned FDA-cleared Phase 1b hypertension study for 2025
- None.
Outgoing CEO, Chris Bunka, to remain on as Chairman of the Board of Directors and Executive Strategic Advisor
KELOWNA, BC / ACCESSWIRE / September 5, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that Chris Bunka, Chief Executive Officer ("CEO") of the Company, is stepping aside for the appointment of Richard Christopher as the new CEO, effective August 31, 2024.
Mr. Christopher is a well-regarded industry veteran with more than three decades of experience in the medical device and pharmaceutical industries, with domestic and international experience in leadership, operations, acquisitions/licensing, business development, strategic planning and capital markets. His career includes an extremely successful tenure with DUSA Pharmaceuticals, Inc. where he was part of team that led a start-up from its operational infancy, through commercialization and profitability and to its eventual sale to Sun Pharmaceuticals Industries Ltd.
"I'm delighted that I have been appointed to lead Lexaria," said Richard Christopher, incoming CEO. "The Company is well positioned for an exciting period of growth centered around the advancement and improvement of drug delivery in the GLP-1 marketplace. We are preparing for an active and collaborative new era for Lexaria in the pharmaceutical industry."
"I will be working with Chris Bunka to make this transition as seamless as possible. On behalf of the Company, I want to thank him for the tremendous contributions he has made to Lexaria over the last 16 years. I'm pleased that Lexaria will continue to benefit from Chris' experience and leadership in his continued role as Chairman of the BOD, as well as in his new advisory role," concluded Richard.
Mr. Bunka has been appointed as Executive Strategic Advisor to the management team where he will continue to provide support and advice to Lexaria. He also remains as Chairman of the Board of Directors of Lexaria and looks forward to providing more focused strategic leadership in that role.
"It has been my greatest honour to serve Lexaria's shareholders in our mutual pursuit of success," said Chris Bunka, outgoing CEO. "Thank you for allowing me to lead the Lexaria community through adversity, change and multiple pivots over the years. Now that DehydraTECH is maturing, it is the right time to ‘pass the torch' to a talented individual better suited to our new focus of pharmaceutical industry collaboration and operations. I have
Under development by Lexaria since 2015, DehydraTECH™ provides superior delivery kinetics to many drugs, allowing them to work more effectively within the human body. After years of animal and human studies across multiple categories of drugs, Lexaria has finally determined that concentrating on cardio-metabolic, diabetes, weight loss and hypertension are the worthiest sectors in which to commercialize this exciting technology.
Lexaria's recent entrance into a Material Transfer Agreement with a pharmaceutical company is the perfect embodiment of our vision for the future of the Company as we look to leverage the DehydraTECH™ technology in ways which could be positively transformative to human health.
Most recently, Mr. Christopher was the Chief Financial Officer at InVivo Therapeutics, a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries. Prior to joining InVivo, Mr. Christopher was the Chief Financial Officer of iCAD, Inc., a company with a focus on therapies and solutions for the early identification and treatment of cancer, where he held both financial and operational responsibilities. Before joining iCAD, Mr. Christopher was Chief Financial Officer and Chief Operating Officer of Caliber Imaging & Diagnostics, Inc., a medical technology company focused on cancer detection imaging solutions, with primary applications in dermatology. Preceding Caliber, Mr. Christopher held various positions of increasing responsibility at DUSA Pharmaceuticals, Inc., a dermatology company focused on the treatment of precancerous skin lesions. He was with DUSA for a period of 12.5 years, where he ultimately served as Chief Financial Officer for 8.5 years before the company's acquisition and integration into Sun Pharmaceuticals Industries Ltd. Mr. Christopher holds a Master of Science in Accounting from Suffolk University and a Bachelor of Science in Finance from Bentley University.
100-Day Plan
During the next 100 days Lexaria is focused on:
execution of the Material Transfer Agreement plans with a recently announced pharmaceutical company
execution of our several ongoing GLP-1 research studies
completion of conceptual design of new independent GLP-1 research studies (TBD)
preparing for the planned 2025 launch of our FDA-cleared Phase 1b hypertension study
About Lexaria Bioscience Corp. & DehydraTECH
DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 46 patents granted and many patents pending worldwide. For more information, please visit www.lexariabioscience.com.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
INVESTOR CONTACT:
George Jurcic - Head of Investor Relations
ir@lexariabioscience.com
Phone: 250-765-6424, ext 202
SOURCE: Lexaria Bioscience Corp.
View the original press release on accesswire.com
FAQ
Who is the new CEO of Lexaria Bioscience Corp (NASDAQ:LEXX)?
What is Lexaria's (NASDAQ:LEXX) focus for drug delivery technology?
What are the key elements of Lexaria's (NASDAQ:LEXX) 100-day plan?
What is the status of Chris Bunka, the former CEO of Lexaria (NASDAQ:LEXX)?
